# US 12,594,257 B2 · Means and methods for improving anti-tumoral efficacy of transmembrane channel protein blockers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,594,257 B2
- Document ID: US12594257B2
- Status: Granted
- Kind: B2
- Application number: 18/565,865
- Filed: 2022-06-02
- Published: 2024-05-09
- Granted: 2026-04-07
- Earliest claimed: 2021-06-03
- Assignees: Ardan Pharma S.A.S.; Universidad De La RepúBlica Oriental Del Uruguay; Institut Pasteur de Montevideo
- Applicants: Ardan Pharma S.A.S.; Universidad De La RepúBlica Oriental Del Uruguay; Institut Pasteur De Montevideo
- Inventors: Marcelo Rafael Hill Mongabure; Mercedes Segovia; Helena Pardo Minetti; Álvaro Mombrú; Sabina Victoria; Analia Castro; Maria Inés Varela Vega
- Web page: https://patentgrep.com/patent/US12594257B2

## CPC

- A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)}
- A61K 9/51: Nanocapsules; {Nanoparticles; (nanotubes A61K9/0092; polymeric micelles A61K9/1075; polymersomes A61K9/1273; pure drug nanoparticles A61K9/14; drug nanoparticles with adsorbed surface modifiers A61K9/141; conjugates, e.g. between drug and non-active nanoparticles, A61K47/50; preparations for in vivo diagnosis A61K49/00; with radioactive substances A61K51/00)}
- A61K 9/5161: {Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin}
- A61K 31/138: Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377)
- A61K 31/166: having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 31/4418: having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention is related to an anti-tumoral composition for the treatment of neoplastic pathologies of malignant kind, and for the treatment of eg7 thymic lymphoma. Said composition comprises a TMEM176A/B inhibitor formulated in nanoparticles. This invention is also related to a method of treating neoplastic pathologies of malignant kind. Said method comprises the steps of administering to a subject a TMEM176A/B inhibitor formulated in nanoparticles.

## Claims

### Claim 1

An anti-tumoral composition, for the treatment of neoplastic pathologies of malignant kind, wherein said composition comprises a TMEM176A/B inhibitor encapsulated in Chitosan nanoparticles, wherein said TMEM176A/B inhibitor is (+)BayK8644.

### Claim 2

An anti-tumoral composition for the treatment of eg7 thymic lymphoma, wherein said composition comprises a TMEM176A/B inhibitor encapsulated in Chitosan nanoparticles, wherein said TMEM176A/B inhibitor is (+)BayK8644.

### Claim 3

A method of treating neoplastic pathologies of malignant kind, wherein said method comprising the steps of administering to a subject a TMEM176A/B inhibitor formulated in Chitosan nanoparticles, wherein said TMEM176A/B inhibitor is (+)BayK8644.